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Racecadotril, via its active metabolite thiorphan, is an inhibitor of the enzyme neutral
endopeptidase (NEP, EC 3.4.24.11), thereby increasing exposure to NEP substrates includ-
ing enkephalins and atrial natriuretic peptide (ANP). Upon oral administration racecadotril is
rapidly and effectively converted into the active metabolite thiorphan, which does not cross
the blood–brain-barrier. Racecadotril has mainly been tested in animal models and patients
of three therapeutic areas. As an analgesic the effects of racecadotril across animal models
were inconsistent. In cardiovascular diseases such as hypertension or congestive heart fail-
ure results from animal studies were promising, probably related to increased exposure to
ANP, but clinical results have not shown substantial therapeutic beneﬁt over existing treat-
ment options in cardiovascular disease. In contrast, racecadotril was consistently effective
in animal models and patients with various forms of acute diarrhea by inhibiting pathologic
(but not basal) secretion from the gut without changing gastro-intestinal transit time or
motility. This included studies in both adults and children. In direct comparative studies
with loperamide in adults and children, racecadotril was at least as effective but exhib-
ited fewer adverse events in most studies, particularly less rebound constipation. Several
guidelines recommend the use of racecadotril as addition to oral rehydration treatment in
children with acute diarrhea.
Keywords: racecadotril, neutral endopeptidase, analgesia, hypertension, congestive heart failure, diarrhea,
loperamide
BACKGROUND
Acute diarrhea is an alteration of normal bowel movements char-
acterized by an increase in the water content, volume, or frequency
of stools. The most common causes are bacterial and viral infec-
tions,particularly rotavirus infections,but the speciﬁc spectrumof
infectious agents depends on the clinical setting (Farthing, 2000).
Such infections cause intestinal hypersecretion leading to ﬂuid loss
and dehydration. Accordingly, oral rehydration is the cornerstone
of treatment, and a standardized glucose-electrolyte solution has
been developed under the auspices of the World Health Orga-
nization and is being used with great success. While this has
signiﬁcantly improved the prognosis of acute diarrhea, it remains
a clinical problem in both the developing world and in industri-
alized countries and, particularly in developing countries, acute
diarrhea is still responsible for the death of two to three million
individuals per year worldwide (Farthing, 2006).
While the infection underlying acute diarrhea typically is self-
limiting, the associated dehydration can be life-threatening, par-
ticularly in children or the elderly. Moreover, a shortening of
the duration of acute diarrhea can also be an important medical
Abbreviations: ANP, atrial natriuretic peptide; i.c.v., intra-cerebroventricular; i.p.,
intra-peritoneal; i.v., intravenous; NEP, neutral endopeptidase.
aim. Therefore, drug treatment can also be a relevant part of the
therapeutic approach, in most cases given on top of rehydration
treatment. Among anti-diarrhea drugs antibiotics are typically
limited to severe cases and other special situations. More fre-
quently, μ-opioid receptor agonists such as codeine, loperamide,
and morphine are being employed, among which loperamide has
become most frequently used (Baldi et al., 2009). Their main
mechanism of action is a reduction of gut motility and accord-
ingly they can cause secondary constipation, abdominal pain, and
abdominal distension.
Against this background, racecadotril has been developed as a
possible alternative to the use of μ-opioid receptor agonists. Fol-
lowing its original registration as a prescription drug in France in
1992 it meanwhile is available in many countries around the globe,
and since 2005 in some of them as a non-prescription drug. The
present manuscript reviews the pharmacodynamic, pharmacoki-
netic, and clinical data for racecadotril and its active metabolite
thiorphan. While the clinical focus of the manuscript is on the
role of racecadotril in the treatment of diarrhea, we will also dis-
cuss other potential uses as they will aid the understanding of the
overall clinical proﬁle of the drug. Racecadotril has been reviewed
in the past (Lecomte, 2000; Matheson and Noble, 2000; Schwartz,
2000) but those articles had a more limited scope and more than
40 new studies have been published since.
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MOLECULAR EFFECTS OF RACECADOTRIL
Racecadotril, formerly known as acetorphan, is a prodrug,which is
converted to the activemetabolite thiorphan (see below; Figure 1).
Acetyl-thiorphan is another active metabolite of racecadotril but
yields only low potency NEP inhibition (Lambert et al., 1993).
Racecadotril has stereoisomers, and the S- and R-isomers of
racecadotril are named ecadotril (also known as BP102 or as sinor-
phan) and retorphan, respectively (Lecomte et al., 1990). Thus,
in the subsequent text racecadotril and thiorphan refer to the
racemate, whereas ecadotril refers to the S-isomer of racecadotril.
At the molecular level racecadotril and thiorphan act by
inhibiting the enzyme neutral endopeptidase (NEP, EC 3.4.24.11;
see below), which is a membrane-metalloendopeptidase also
known as enkephalinase. NEP has various substrates including
enkephalins (hence the name enkephalinase) but also atrial natri-
uretic peptide (ANP), brain natriuretic peptide, substance P, neu-
rotensins, and neuropeptide Y (van Kemmel et al., 1996; Turvill
and Farthing, 1997). Therefore, NEP inhibition can potentially
affect any of these mediators and observed in vivo effects in dif-
ferent organ systems may not always relate to the same enzyme
substrate (see below).
The ﬁrst report on thiorphan described an IC50 of 4.7 nM
for NEP inhibition in striatal membranes (Roques et al., 1980).
Inhibition of puriﬁed NEP activity from mouse brain yielded
afﬁnity estimates (K i values) of 6.1 and 4500 nM for thiorphan
and racecadotril, respectively; however,when racecadotril was pre-
incubated with rat brain membranes for 15min, an apparent K i
value of 8.6 nM was observed, probably reﬂecting rapid in vitro
conversion to thiorphan (Lecomte et al., 1986). A similar study
reported an IC50 of 1.8 nM for thiorphan with racecadotril being
1000 times less potent and acetyl-thiorphan having a value of
316 nM (Lambert et al., 1993, 1995). For in vitro inhibition of rat
kidney NEP an IC50 of 5.4 nM was reported (Fink et al., 1995),
apparently reﬂecting in vitro conversion to thiorphan as shown
before in rat brain (Lecomte et al., 1986).
A second approach to assess thiorphan afﬁnity for NEP has
been radioligand binding studies. In saturation binding studies in
various mouse tissues [3H]-thiorphan exhibited an afﬁnity (Kd
value) of 0.46–0.77 nM, and the density of [3H]-thiorphan bind-
ing sites was well correlated with measured NEP activity in a panel
of 11 different mouse tissues (de la Baume et al., 1988). Similar
saturation binding experiments using [3H]-racecadotril as the lig-
and reported an afﬁnity of 4–5 nM in rats (Fournet-Bourguignon
et al., 1992), apparently reﬂecting conversion of racecadotril to
thiorphan in the assay (Lecomte et al., 1986). A third approach has
been to measure occurrence of enkephalin break-down products
such as the tripeptide Tyr–Gly–Gly, and in isolated rat brain slices
this has yielded an IC50 of 9 nM for thiorphan (Giros et al., 1986).
Correspondingly, it has repeatedly been observed that oral,
intra-peritoneal (i.p.), or intravenous (i.v.) administration of
racecadotril or ecadotril leads to a rapid reduction in NEP activity
in plasma (Spillantini et al., 1986; Lecomte et al., 1990; Dussaule
et al., 1991, 1993; Stasch et al., 1996; Duncan et al., 1999; Lecomte,
2000), kidney (Gros et al., 1989), and brain (Lecomte et al., 1986;
Spillantini et al., 1986). Such studies were performed with consis-
tent results in rats (Lecomte et al., 1986; Stasch et al., 1996;Wegner
et al., 1996; Duncan et al., 1999), mice (Lecomte et al., 1986), and
humans (Spillantini et al., 1986; Gros et al., 1989; Lecomte et al.,
1990; Dussaule et al., 1991, 1993; Lecomte, 2000). In vivo inhi-
bition of enkephaline metabolite formation was also observed in
rat spinal cord after i.v. racecadotril (Llorens-Cortes et al., 1989)
or in mouse striatum after intra-cerebro-ventricular (i.c.v.) thior-
phan (Llorens-Cortes et al., 1986). Of note, assessment of NEP
inhibition by measuring endogenous enkephalins can yield false
negative results as enkephalines can also be metabolized by other
aminopeptidases such as EC 3.4.11.2, and this can compensate
for NEP inhibition (Bourgoin et al., 1986; Llorens-Cortes et al.,
1986). As ANP also is a NEP substrate, NEP inhibition can also be
assessed by changes of ANP concentrations in plasma and urine,
which are described in detail in Section “Cardiovascular Studies.”
The R- and S-stereoisomers of thiorphan inhibited puriﬁed
NEP activity with similar potency 1.7 vs. 2.2 nM, respectively,
and occurrence of the enkephalin metabolite Tyr–Gly–Gly with
an IC50 of 10 nM (Giros et al., 1987). In the same study occur-
rence of Tyr–Gly–Gly in mouse striatum was also inhibited with
similar potency by i.v. administration of ecadotril and retorphan,
the stereoisomers of racecadotril (ED50 0.4 and 0.8mg/kg, respec-
tively). On the other hand,with the same oral dose of ecadotril and
retorphan inhibition of the in vivo binding of [3H]-racecadotril in
mouse kidney was somewhat stronger for the S-isomer (Lecomte
et al., 1990). Similarly, a 30-mg oral dose of ecadotril produced
somewhat greater inhibition of NEP activity and ANP levels in
human plasma than the same dose of retorphan (Lecomte et al.,
1990).
In conclusion, racecadotril and its metabolite acetyl-thiorphan
are only low potency NEP inhibitors. However, racecadotril is
rapidly converted to the active metabolite thiorphan in vitro
(Lecomte et al., 1986) and in vivo (see Pharmacokinetic and
FIGURE 1 | Chemical structures of racecadotril and its two metabolites thiorphan and acetyl-thiorphan.The blue arrows indicate the sites of
metabolization; the asterisk indicates the chiral center of the molecule.
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Drug–Drug Interaction Studies), and thiorphan is an about
1000 times more potent NEP inhibitor than racecadotril with
reported potencies of 0.4–9 nM. The S-isomers of racecadotril
and thiorphan may be slightly more potent than the R-isomers.
PHARMACOKINETIC AND DRUG–DRUG INTERACTION
STUDIES
ANIMAL PHARMACOKINETIC STUDIES
In mice, following i.v. administration, racecadotril was rapidly
metabolized to thiorphan; thus, 30min after the injection only
thiorphan was recovered from the kidney whereas the parent com-
pound racecadotril was not detected (de la Baume et al., 1988).
In rats 92% of a single-dose (10mg/kg) of radioactively labeled
racecadotril was eliminated within 24 h (Matheson and Noble,
2000).
HUMAN PHARMACOKINETIC STUDIES
Racecadotril is rapidly absorbed following oral administration.
For example, in a single-dose, placebo-controlled, double-blind
cross-over study racecadotril doses of 30, 100, and 300mg reached
Cmax within 60min after oral administration; the latter two doses
were associated with signiﬁcant inhibition of plasma NEP activity
seen as early as 30min after ingestion, and that inhibition exhibited
a t 1/2 of 3 h (Lecomte, 2000; Matheson and Noble, 2000). A single-
dose study in healthy elderly people reported similar ﬁndings
(Matheson and Noble, 2000). After ingestion of a single oral dose
of 300mg racecadotril plasma thiorphan levels peaked after 60min
reaching 805–1055 nM; after 240min plasma levels were still at
92–204 nM (Hinterleitner et al., 1997). In a more recent study, a
well validated liquid chromatography/tandem mass spectrometry
method has been used to detect thiorphan in human plasma; 20
volunteers received a single oral dose of 200mg racecadotril,which
resulted in a thiorphan Cmax of 520 ng/mL, a tmax of 1.35 h and
a t 1/2 of 6.14 h (Xu et al., 2007). The pharmacokinetic properties
of racecadotril are similar with chronic dosing as observed in a
placebo-controlled, double-blind study with 30, 100, and 300mg
racecadotril being given orally thrice daily for 7 days, where phar-
macokinetic parameters were similar on day 1 and day 7 and
to the values observed in the single-dose studies (Matheson and
Noble, 2000), indicating lack of accumulation upon chronic dos-
ing. Concomitant food intake does not modify the bioavailability
of racecadotril but peak NEP inhibition is delayed by about 90min
(data on ﬁle).
After oral administration racecadotril is rapidly and effectively
metabolized to the active metabolite thiorphan which is the pre-
dominant species detected in plasma; the occurrence of thiorphan
coincides in time with the inhibition of plasma NEP (Hinterleit-
ner et al., 1997; Xu et al., 2007). Thiorphan has a plasma protein
binding of approximately 90% (data on ﬁle).
An important question for any drug interfering with the
endogenous opioid system is whether it crosses the blood–brain-
barrier, i.e., whether upon oral racecadotril administration parent
compound or active metabolite reaches relevant levels in the
brain to cause NEP inhibition. Animal studies suggest that cen-
tral nervous effects can occur after parenteral administration of
racecadotril but not after oral racecadotril or parenteral thior-
phan administration (see Studies on Central Nervous System
Function); this is the apparent result of the combination of the
rapid conversion of absorbed racecadotril to thiorphan and the
lack of thiorphan passage through the blood–brain-barrier due
to its less lipophilic chemical structure (Figure 1). In line with
these animal data it has been reported that i.v. administration
of racecadotril causes quantitatively similar NEP inhibition in
plasma and cerebrospinal ﬂuid in ﬁve healthy volunteers as com-
pared to saline infusion (Spillantini et al., 1986), whereas a single
high oral racecadotril dose (20mg/kg) to two volunteers caused a
marked reduction of plasma NEP activity within 30min but did
not affect liquor NEP activity (Lecomte, 2000). In accordance with
the proposed lack of central nervous effects of orally administered
racecadotril, a placebo-controlled cross-over study in 12 subjects
being treated with 300mg/kg racecadotril for 3 days did not detect
any impairment of vigilance (Lecomte, 2000).
The active racecadotril metabolite thiorphan is converted to
inactive metabolites, but the pathways mediating this conversion
have not been characterized in great detail. While two studies
using different methodological approaches have reported that
racecadotril inhibits CYP 3A4-mediated formation of metabolites
of the cancer chemotherapeutic drug irinotectan with an IC50 of
46μM in human liver microsomes (Haaz et al., 1998a,b), it should
benoted that this concentration is equivalent to about 10,000 times
the potency of thiorphan for NEP inhibition. Thus, in concentra-
tions which are achieved by therapeutic doses racecadotril is nei-
ther an inhibitor nor an inducer of cytochrome P450 enzymes and
also not a substrate of the P-glycoprotein transporter (data on ﬁle).
Accordingly, to date no interactions with other medicinal products
have been identiﬁed and speciﬁcally concomitant treatment with
loperamide or nifuroxazide does not affect the pharmacokinet-
ics of racecadotril (data on ﬁle). Moreover, racecadotril does not
modify protein binding of active substances strongly bound to
proteins such as tolbutamide, warfarin, niﬂumic acid, digoxin, or
phenytoin (data on ﬁle). The elimination of the inactive thiorphan
metabolites occurs mainly via the renal route (data on ﬁle).
STUDIES ON CENTRAL NERVOUS SYSTEM FUNCTION
As discussed in Section “Pharmacokinetic and Drug–Drug Inter-
action Studies,”parenteral administration of racecadotril can have
central nervous effects but these are not apparent with oral
racecadotril or parenteral thiorphan treatment. Most effects of
racecadotril and its metabolites on brain function apparently
are mediated by inhibition of enkephalin degradation, as opiate
receptor antagonism in many cases abolishes them (see below).
ANALGESIA
Based on the role of morphine and other opiates in pain control, it
was an obvious choice to test racecadotril in various pain models.
The results have been rather inconsistent across models but much
more consistent within models indicating that NEP inhibition
selectively targets certain pain pathways. Thus, racecadotril was
analgesic in the hot-plate jump test in unspeciﬁed mice with i.c.v.
administration (Roques et al., 1980) and with i.v. administration
in Swiss albino (Lecomte et al., 1986; Costentin et al., 1998),NMRI
(Lambert et al., 1993, 1995) and DBA/2J mice but not C57BL/6J
mice (Michael-Titus et al., 1989). Interestingly, in the latter study
racecadotril increased locomotion in both strains, indicating that
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the difference in analgesic effect does not reﬂect a pharmacokinetic
strain difference. In NMRI mice i.v. acetyl-thiorphan and thior-
phan were also effective in this model, although thiorphan less
than the more lipophilic acetyl-thiorphan and racecadotril (Lam-
bert et al., 1993, 1995). I.v. racecadotril was also analgesic in Swiss
albino mice in the tail-withdrawal and the phenylbenzoquinone-
induced writhing test (Lecomte et al., 1986). In an arthritis-based
pain model in rats (vocalization induced by applying pressure to
the left hind paw) racecadotril also exhibited analgesic activity
(Kayser and Guilbaud, 1983), but this was weaker than that of the
mixed peptidase inhibitor kelatorphan in the same model (Kayser
et al., 1989). In the same test racecadotril was not analgesic in non-
arthritic rats (Kayser and Guilbaud, 1983). In unspeciﬁed mice
i.c.v. thiorphanwas ineffective in the tail removal test but enhanced
the analgesic effects of several enkephalines which are NEP sub-
strates but not of others which are not NEP substrates (Roques
et al., 1980). Moreover, racecadotril did not exhibit analgesic prop-
erties in the hot-plate licking test in Swiss albino (Lecomte et al.,
1986) or NMRI mice (Lambert et al., 1993) or in albino mice in
the tail immersion test, but enhanced the anti-nociceptive effect
of an exogenously administered enkephalin in the latter model
(Livingston et al., 1988). In GB1 mice in the acetic acid-induced
abdominal constriction assay racecadotril was effective only at
subcutaneous doses of 10mg/kg and higher (Gray et al., 1998).
Upon chronic stimulation the opioid system can exhibit both
desensitization and sensitization. Thus, the analgesic response to
i.v. racecadotril was blunted after 14 days of i.c.v. treatment with
thiorphan in rats (Bousselmame et al., 1991a). However, no cross-
desensitization between racecadotril and morphine was observed
in mice (Bousselmame et al., 1991b) or rats, and in the latter
also no cross-sensitization for locomotive effects was observed
(Khallouk-Bousselmame and Costentin, 1994).
It has also been tested whether racecadotril can enhance anal-
gesic effects of other treatments. Thus, racecadotril or thiorphan
enhanced naloxone-sensitive analgesia induced by transcranial
electrostimulation in rats (Malin et al., 1989) or by nefopam
in mice (Gray et al., 1999), and also enhanced analgesic effects
of electroacupunture in rats (Zhou et al., 1990). In the acetic
acid-induced abdominal constriction pain model in GB1 mice
racecadotril enhanced the analgesic effect of morphine and of
anti-depressants such as dothiepine and amitriptyline (Gray et al.,
1998). On the other hand, racecadotril did not enhance naloxone–
sensitive analgesic effects in four different pain models in mice
(Michael-Titus and Costentin, 1987), and neither i.v. racecadotril
nor i.c.v. thiorphan enhanced analgesic effects of dopamine recep-
tor agonists in mice (Michael-Titus et al., 1990a). Another type of
interaction between pain-related pathways was suggested by ﬁnd-
ings in mice in which nociceptin attenuated the analgesic response
to racecadotril (Costentin et al., 1998).
In conclusion, racecadotril has direct analgesic effects and can
enhance analgesic effects of some other types of drugs in some but
not all pain models, but such studies were largely restricted to par-
enteral administration. Similar to direct opioid receptor agonists,
racecadotril-induced analgesia can undergo desensitization upon
long-term exposure but despite both morphine and racecadotril
effects involving opioid receptors, they did not exhibit cross-
desensitization. As the anti-nociceptive effects of racecadotril are
restricted to some model systems, it can be expected that, if at
all, racecadotril would be effective only in some forms of pain in
patients and only upon parenteral administration; however, a clin-
ical testing of potential analgesic effects of racecadotril in patients
has not been reported to our knowledge.
OTHER NERVOUS SYSTEM STUDIES
The administration of natural or synthetic opioid receptor ago-
nists elicits a locomotor response in rodents,which is considered to
be an index of the activity of mesolimbic dopaminergic neurons.
In both mice and rats i.v. racecadotril was reported to enhance
locomotion in mice and rats in a naloxone–sensitive manner, and
that response was blocked by a dopamine receptor antagonist and
enhanced by a dopamine uptake inhibitor (Michael-Titus et al.,
1987, 1990b). Similar to the analgesic racecadotril response (see
Analgesia), the locomotor racecadotril response also was desen-
sitized following a 14-day i.c.v. treatment with thiorphan (Bous-
selmame et al., 1991a). In line with the idea that racecadotril can
affect dopaminergic transmission in the brain, it was found that i.v.
racecadotrilmodulates dopaminergic transmission in rat olfactory
tubercle but not striatum (Dourmap et al., 1990).
Both the opioid and the dopamine system in the brain are
prone to addiction. Therefore, it was important to ﬁnd that
racecadotril did not exhibit abuse potential in rats or monkeys
in doses up to 50mg/kg (Knisely et al., 1989). Nevertheless,
i.p. racecadotril prevented some but not all withdrawal symp-
toms in opioid-habituated mice and rats (Livingston et al., 1988;
Dzolic et al., 1992). However, racecadotril alone was ineffective
in inhibiting naloxone-induced morphine withdrawal symptoms
in mice in another study, but a combination of subthreshold
doses of racecadotril, CCK-4, and caerulein was effective (Bourin
et al., 1999). In a double-blind, double-dummy, clinical proof-of-
concept study in 19 heroin-addicted patients comparing 50mg i.v.
racecadotril and 75μg oral clonidine; racecadotril appeared more
effective than clonidine against objective withdrawal symptoms
as quantiﬁed by the Himmelsbach scale, whereas both treatments
were similarly effective against subjective withdrawal symptoms
(Hartmann et al., 1991).
Some studies have explored potential metabolic effects of
racecadotril. In sheep oral and i.v. administration of racecadotril
increased food intake, whereas i.c.v. thiorphan reduced it; as oral
racecadotril treatment does not lead to NEP inhibition in the
brain and as i.c.v. thiorphan did not mimick the racecadotril
effects, this appears to be a peripheral effect (Riviere and Bueno,
1987). Moreover, naltrexone blocked the former but not the latter
effect, indicating an involvement of peripheral opioid receptors. A
study with i.v. racecadotril in cats reported increases in sham food
intake (Bado et al., 1989). In rats i.v. racecadotril caused naloxone-
insensitive dose-dependent lowering of blood glucose which was
accompanied by increased plasma insulin and C-peptide levels
(Wu et al., 2010). While racecadotril did not affect insulin release
from isolated pancreatic islets, the muscarinic receptor antagonist
atropine blocked and the cholinesterase inhibitor physostigmine
enhanced the racecadotril-induced insulin elevation, indicating
that they may occur via modulation of parasympathetic nerve
activity. In a follow-up study the same investigator group provided
evidence that i.v. racecadotril and i.c.v. thiorphan directly inhibit
Frontiers in Pharmacology | Gastrointestinal Pharmacology May 2012 | Volume 3 | Article 93 | 4
Eberlin et al. Neutral endopeptidase inhibitor racecadotril
an insulin-degrading enzyme in the brain, and that brain insulin
acts via the vagal nerve on plasma glucose (Lee et al., 2011). The
clinical ﬁndings of these intriguing observations have not been
explored in patients to our knowledge.
In a mouse behavioral dispair test, a model system for anti-
depressant effects, immobility time was reduced by 10mg/kg i.v.
or 50mg/kg i.p. in mice (Lecomte et al., 1986). Moreover, it was
reported that thiorphan can provide neuroprotection in newborn
mice (Medja et al., 2006).
CARDIOVASCULAR STUDIES
Most effects of racecadotril and its metabolites in the cardio-
vascular system apparently are largely mediated by inhibition
of degradation of the natriuretic peptides. Thus, racecadotril-,
ecadotril-, or thiorphan-induced inhibition of ANP break-down
and/or elevation of ANP levels have been demonstrated in rats
(Fink et al., 1996; Stasch et al., 1996), mice (Gros et al., 1989,
1990a,b; Lecomte et al., 1990; Stasch et al., 1996), and humans
(Gros et al., 1989; Dussaule et al., 1991, 1993; Piquard et al., 2002)
as assessed in plasma (Gros et al., 1989, 1990b; Lecomte et al., 1990;
Dussaule et al., 1991, 1993; Schmitt et al., 1994; Fink et al., 1996;
Stasch et al., 1996; Piquard et al., 2002) or in tissues such as kidney
(Gros et al., 1989, 1990a). The increase in circulating ANP con-
centrations is typically associated with increased concentrations
of the ANP-generated second messenger cyclic GMP in plasma
(Dussaule et al., 1993; Stasch et al., 1995, 1996; Cleland and Swed-
berg, 1998; Piquard et al., 2002) or urine of animals and patients
(Lecomte et al., 1990; Dussaule et al., 1991; Schmitt et al., 1994;
Stasch et al., 1995, 1996; Cleland and Swedberg, 1998; Kimura
et al., 1998; Duncan et al., 1999). The racecadotril and ecadotril
effects on plasma ANP may be even more pronounced in patients
(see below). Based on these ﬁndings, racecadotril has been studied
in various animal models, in healthy volunteers, and in patient
groups in which an increased exposure to ANP has been deemed
beneﬁcial.
An important physiological effect of ANP is promoting diure-
sis and natriuresis. Based on the consistent racecadotril effects
on ANP, effects of racecadotril have been studied in various ani-
mal models and in humans. Thus, oral racecadotril treatment
increased natriuresis in normotensive rats, which was accompa-
niedby enhanceddiuresis in some (Bralet et al., 1990) but not other
studies (Stasch et al., 1995, 1996). Racecadotril-induced diure-
sis and natriuresis have also been reported in healthy volunteers
(Gros et al., 1989; Lecomte et al., 1990). This was accompanied
by an elevated glomerular ﬁltration rate and lowered renal blood
ﬂowwhereas plasma aldosterone concentration, renin activity, and
mean arterial bloodpressurewere not altered (Schmitt et al., 1994).
TREATMENT OF ARTERIAL HYPERTENSION
Racecadotril has been tested in various animal models of
hypertension, speciﬁcally for its ability to lower blood pres-
sure, improve renal function, and to prevent or reverse organ
hypertrophy. These models include spontaneously hypertensive
rats (Bralet et al., 1990) and its stroke-prone substrain (Stasch
et al., 1995), transgenic rats harboring a mouse renin gene
(Stasch et al., 1996), hypertension induced by treatment with
the immunosuppressant cyclosporine A in rats (Takeda et al.,
2000), and the rat deoxycorticosterone acetate-salt model of
mineralocorticoid-induced hypertension (Ito et al., 1999). Blood
pressure lowering by oral racecadotril or ecadotril was consis-
tently shown (Stasch et al., 1995, 1996; Ito et al., 1999; Takeda
et al., 2000). In a ﬁrst pilot study in 12 hypertensive patients
receiving increasing sinorphan doses (25–200mg bid) for a total
of 6 weeks a dose-dependent blood pressure reduction was also
observed (Lefrancois et al., 1990). In a subsequent randomized,
double-blind clinical pilot study with a cross-over design in 16
hypertensive patients racecadotril was less effective than captopril
in lowering blood pressure, but the combination of both drugs
was more effective than either monotherapy (Favrat et al., 1995).
In line with the effects in normotensive animals and healthy
human volunteers, racecadotril also increased diuresis and/or
natriuresis in spontaneously hypertensive rats (Bralet et al., 1990),
in transgenic rats (Stasch et al., 1996) and in deoxycorticos-
terone acetate-salt-treated rats (Ito et al., 1999) whereas numerical
increases of diuresis and natriuresis did not yield statistical sig-
niﬁcance in stroke-prone spontaneously hypertensive rats (Stasch
et al., 1995).
A prognostically relevant complication of hypertension is the
development of hypertrophy of the heart and other cardiovascular
organs. In this regard, chronic treatmentwith racecadotril reduced
heart hypertrophy in stroke-prone spontaneously hypertensive
rats (Stasch et al., 1995), in transgenic rats (Stasch et al., 1996) and
in deoxycorticosterone acetate-salt-treated rats (Ito et al., 1999). A
reduction of renal enlargements was observed less consistently in
these studies.
Taken together these studies demonstrate beneﬁcial effects of
treatment with racecadotril on blood pressure, renal function, and
cardiac hypertrophy in various animal models of hypertension,
which is in line with the elevated ANP levels in such animals.
While clinical pilot studies have conﬁrmed blood pressure low-
ering effects in hypertensive patients, these were too modest in
comparison to established anti-hypertensive treatments to war-
rant further clinical investigation of racecadotril in this indication;
potential enhancement of blood pressure lowering by other drugs
was also deemed insufﬁcient to be of clinical relevance.
TREATMENT OF CONGESTIVE HEART FAILURE
Congestive heart failure leads to atrial dilatation which is the
most important physiological stimulus for ANP secretion. This
enhanced ANP secretion is generally seen as a counter-measure
to increase diuresis and natriuresis and thereby lower cardiac
after-load. Accordingly, racecadotril has been evaluated in ani-
mal models and in patients with heart failure. Animal models of
heart failure in which racecadotril or ecadotril have been tested
include rats with volume overload due to aortic valve insufﬁciency
(Kimura et al., 1998) or to an atrio-ventricular ﬁstula (Wegner
et al., 1996), rats after a myocardial infarction (Duncan et al.,
1999), dogs with coronary microembolization (Olivier et al., 2000;
Mishima et al., 2002), and dogs with heart failure due to sino-atrial
pacing (Solter et al., 2000).
In line with the ﬂuid retention, an activation of the renin–
angiotensin system is a hallmark of congestive heart failure. Such
activation was mitigated by treatment with racecadotril in animal
models (Wegner et al., 1996; Kimura et al., 1998; Duncan et al.,
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1999).A similarly reduced activity of the renin–angiotensin system
was observed in an early and short-term pilot study in heart fail-
ure patients (Kahn et al., 1990) but not in a larger chronic study in
such patients (Cleland and Swedberg, 1998).Whether indirectly by
reducing activity of the renin–angiotensin system or more directly
by increasing ANP exposure, diuretic and/or natriuretic effects
of racecadotril were observed in the volume overload rats (Weg-
ner et al., 1996), coronary microembolization dogs (Olivier et al.,
2000), and in dogs with pacing-induced heart failure (Solter et al.,
2000) but not in post-myocardial infarction rats (Duncan et al.,
1999). Accordingly, improvements of the cardiac pump function
were observed inmost of thesemodels (Kimura et al., 1998;Olivier
et al., 2000; Mishima et al., 2002), whereas blood pressure did not
change (Mishima et al., 2002).
Some of these heart failure models, particularly those involving
volume or pressure overload typically lead to cardiac hypertrophy.
In line with the other ﬁndings it has been found that chronic
racecadotril treatment ameliorates such cardiac hypertrophy in
the volume overload rat models (Wegner et al., 1996; Kimura
et al., 1998). Similarly, racecadotril treatment also reduced car-
diac hypertrophy in the dog microembolization model (Mishima
et al., 2002). However, in the post-myocardial infarction rat model
neither racecadotril nor perindopril alone reduced development
of cardiac hypertrophy whereas their combination did (Duncan
et al., 1999).
In accordancewith the observed increase in plasmaANF and/or
urinary cGMP, three studies have explored whether racecadotril or
ecadotril may have therapeutic beneﬁt in heart failure patients. In
a series of small pilot studies in patients with severe heart fail-
ure (left ventricular ejection fraction 20%), 2 days of ecadotril
treatment doubled plasma ANP levels despite starting from a
markedly elevated baseline (Kahn et al., 1990). This was accompa-
nied by a reduced renin activity and pulmonary capillary wedge
pressure. Based on those encouraging ﬁndings a clinical, placebo-
controlled dose-ranging study (50–400mg ecadotril twice daily
for 6months) was performed in 259 patients with moderate heart
failure (left ventricular ejection fraction of <35%; Cleland and
Swedberg, 1998). This conﬁrmed a dose-dependent increase in
plasma and urinary cGMP but patients did not show reduced
activation of the renin–angiotensin system or, more importantly,
clinical improvement. Another study in a similar population of 50
moderate heart failure patients with 10weeks of treatment with
increasing racecadotril doses (up-titration from50 to 400mg twice
daily) also failed to demonstrate clinical improvement (O’Connor
et al., 1999).
Taken together racecadotril has shown promising ﬁndings in
animal models of congestive heart failure but patient studies have
not conﬁrmed a sufﬁcient clinical potential to warrant further
development in this indication.
TREATMENT OF OTHER CARDIOVASCULAR CONDITIONS
Racecadotril has also been tested in animal models and/or clinical
pilot studies for various other indications related to cardiovascu-
lar function. Studies in rats have reported that i.v. racecadotril
may protect the heart against adrenaline-induced arrhythmia
(Lishmanov et al., 2001) or against arrhythmia induced by short
ischemia–reperfusion episodes (Naryzhnaia et al., 2001), the latter
effect being blocked by a δ-opioid receptor antagonist. In a mouse
model of pulmonary hypertension ecadotril was found to have
synergistic beneﬁcial effects with sildenaﬁl (Baliga et al., 2008).
In a single-dose pilot study in liver cirrhosis patients
racecadotril 30 and 100mg increased plasma ANP and cGMP
and caused a transient diuresis and natriuresis response relative
to placebo; the activity of the renin–angiotensin system appar-
ently was not affected in these patients (Dussaule et al., 1991). In a
single-dose cross-over pilot study in chronic renal failure patients
100mg ecadotril inhibited enkephalinase, increased plasma cGMP
and natriuresis; aldosterone, glomerular ﬁltration rate, or blood
pressure were not affected (Dussaule et al., 1993). Finally, a sin-
gle dose of 200mg ecadotril increased plasma endothelin-1, ANP,
and cGMP and diuresis and natriuresis in a randomized placebo-
controlled study in heart transplant recipients (Piquard et al.,
2002).
STUDIES IN THE GASTRO-INTESTINAL TRACT
Most effects of racecadotril and itsmetabolites on gastro-intestinal
function apparently are mediated by inhibition of enkephalin
degradation, as opiate receptor antagonism in many cases abol-
ishes them (see below). However, an inhibition of the degradation
of neuropeptide Y and the closely related peptide YY by NEP
may also be involved as both of these peptides have anti-secretory
effects in the gut (Playford and Cox, 1996).
EXPERIMENTAL STUDIES RELATED TO DIARRHEA
It is well established that enkephalines have potent anti-secretory
properties in the gut but do not affect gut motility (Turvill and
Farthing, 1997). In an initial study in rats, i.v. racecadotril inhib-
ited castor oil-induced diarrhea, an effect which was abolished by
the opioid receptor antagonist naloxone (Lecomte et al., 1986).
Such ﬁndings in the castor oil model of diarrhea were conﬁrmed
in rats with oral racecadotril and with i.v. thiorphan; they were
blocked by subcutaneous but not by i.c.v. naloxone, indicating that
the opioid receptors mediating this effects are located peripherally
(Marcais-Collado et al., 1987). Racecadotril also reduced castor
oil-induced diarrhea in human volunteers in a placebo-controlled
study (Baumer et al., 1992).
To explore the underlying mechanism of anti-diarrhea effects
of racecadotril, several studies have been performed. Thus, exces-
sive ﬂuid secretion from the gut is a pathophysiological hallmark
of diarrhea. Racecadotril inhibited cholera toxin-induced but not
basal secretion in canine jejunum (Primi et al., 1999). This was
conﬁrmed in a parallel group study in human volunteers, in which
cholera toxin was administered by segmental perfusion directly
into the proximal jejunum (Hinterleitner et al., 1997). In another
study, racecadotril inhibited secretion induced by rotavirus infec-
tion in an in vitro model of intestinal secretion, Caco-2 cells
(Guarino et al., 2009), a model which may be of value because
rotavirus infection is a very frequent cause of childhood diarrhea.
A potential complication of diarrhea treatment is inhibition
of intestinal motility as it can lead to secondary constipation
and, perhaps even more important, intestinal retention of harm-
ful infectious organisms. In rats oral 40mg/kg racecadotril was
reported not to affect gastro-intestinal transit time, whereas
2mg/kg loperamide did (Marcais-Collado et al., 1987). Using the
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same approach in mice, 20mg/kg i.v. of racecadotril or thior-
phan or 0.5mg/kg oral loperamide also did not signiﬁcantly affect
transit time, whereas 10mg/kg oral or 0.5mg/kg i.v. loperamide
signiﬁcantly prolonged it (Marcais-Collado et al., 1987). A poten-
tial consequence of effects on gastro-intestinal transit time was
explored in newborn piglets, in which a 4-day oral treatment with
20mg/kg racecadotril twice daily did not signiﬁcantly affect E. coli
content of the proximal jejunum,whereas 1mg/kg oral loperamide
twice daily markedly increased it; accordingly, the E. coli content
of the stool was signiﬁcantly reduced by loperamide but not by
racecadotril (Duval-Ilfah et al., 1999). In placebo-controlled stud-
ies in human volunteers racecadotril treatment for up to 1week
also did not modify oro-coecal, colonic or overall gastro-intestinal
transit times (Baumer et al., 1989; Bergmann et al., 1992).
In conclusion, both racecadotril and direct μ-opioid receptor
agonists have effects on the gut which lead to limitation of patho-
logical ﬂuid loss. While the receptor agonists do so primarily by
prolonging transit time and hence providing more opportunity
for ﬂuid reabsorption, racecadotril does so by inhibiting ﬂuid
secretion; the latter may be preferable as it directly targets the
primary pathophysiological mechanism underlying acute diar-
rhea and also reduces the chance of retention of infectious agents
in the gut.
NON-DIARRHEA GASTRO-INTESTINAL STUDIES
I.v. administration of racecadotril was shown to inhibit gastric
secretion in cats induced by pentagastrin, histamine or 2-deoxy-
d-glucose in a naloxone-sensitive manner, whereas the meal-
induced secretion was not affected (Bado et al., 1987). In rats
i.v. racecadotril and i.c.v. thiorphan, but not i.v. thiorphan, inhib-
ited gastric acid secretion; this was no longer observed following
vagotomy, indicating a central nervous system-mediated effect
(Chicau-Chovet et al., 1988). In mice i.p. racecadotril and thior-
phan given prior to a fatty meal enhanced gastric emptying in
a naloxone-sensitive manner; gastric emptying in response to a
non-fat meal was enhanced by low and inhibited by a high thior-
phan dose in a naloxone–resistant manner, and racecadotril was
without signiﬁcant effect under these conditions (Liberge et al.,
1988).
Effects of racecadotril have also been investigated in the feline
gall bladder. In a feline cholecystitis model racecadotril inhibited
ﬂuid secretion in a naloxone–sensitive manner, but did not block
ﬂuid transport in the normal gall bladder (Jivegard et al., 1989). In
that study racecadotril also caused transient gall bladder contrac-
tion and increased bile outﬂow from the liver. In another study
in the same species i.v. racecadotril but not i.v. thiorphan caused
naloxone–sensitive contraction of the spincter Oddi, indicating a
central nervous system-mediated effect (Thune et al., 1992).
In a controlled cross-over study in 10 healthy volunteers,
2.5mg/kg i.v. racecadotril attenuated relaxation of the lower
esophagus sphincter but did not affect contraction (Chaussade
et al., 1988). Racecadotril enhanced the propagation of electrical
signals in the distal colon in rats in the fasted and fed state in
a naloxone–sensitive manner (Benouali et al., 1993). In a study
in healthy volunteers racecadotril produced an atropine-resistant
promotion of electrical activity in the rectum, which was absent
in patients with Hirschsprung’s disease (Grimaud et al., 1989).
PLACEBO-CONTROLLED STUDIES IN ADULTS WITH ACUTE DIARRHEA
The data of all controlled studies with racecadotril in the treat-
ment of acute diarrhea in adults are summarized for efﬁcacy in
Table 1 and for adverse events in Figure 2. The original regis-
tration of racecadotril as a treatment for acute diarrhea in adults
in France in 1992 was based on three placebo-controlled studies.
In a double-blind, placebo-controlled, randomized dose-ranging
study 49–55 patients per group with acute diarrhea presumed to
be due to food poisening or infection-related received 30, 100, or
300mg racecadotril or placebo three times per day until recovery
for up to 10 days (data on ﬁle). The primary outcome parameter
was time to cure,whichwas 68.4,69.6,65.0, and 72.0 hwith 30,100,
and300mg racecadotril andplacebo, respectively (not signiﬁcant).
Secondary outcome parameters included number of diarrhoic
stools in the ﬁrst 10 h (2.0–2.2 with the three racecadotril doses
as compared to 2.7 days with placebo; p = 0.06) and in ﬁrst 3 days
(6.8–7.7 with the three racecatodril doses as compared to 8.6 days
with placebo; p = 0.03). The incidence of the adverse events anal
burning, painful anal contractions, spontaneous abdominal pain,
nausea, vomiting, loss of appetite, asthenia, and insomnia did not
differ signiﬁcantly between groups.
In a double-blind, randomized, placebo-controlled study adult
out-patients with acute diarrhea of presumed infectious origin
having started less than 5 days before (95 on racecadotril, 98 on
placebo) were treated with an initial dose of 200mg racecadotril
followed by an additional 100mg dose after each unformed bowel
movement until recovery or for a maximum of 10 days (Baumer
et al., 1992). Resolution of diarrhea occurred signiﬁcantly faster in
a Kaplan–Meier type analysis with racecadotril than with placebo,
e.g., on day 4 the cumulative probability of recovery was 75%
with racecadotril vs. 37% with placebo. Accordingly, mean dura-
tion of treatment was 3.0± 0.2 days with active treatment vs.
4.4± 0.3 days with placebo. Several secondary endpoints includ-
ing anal burning, spontaneous abdominal pain, nausea, anorexia,
pain on abdominal palpation, and abdominal distension were also
signiﬁcantly improvedby racecadotril as compared toplacebo.The
percentage of patients reporting adverse effects with racecadotril
and placebo was 16.8 vs. 18.4%, respectively.
In another double-blind, parallel group, placebo-controlled
study 70 adult patients with acute diarrhea of presumed infec-
tious origin were included and randomized to receive 100mg
racecadotril or placebo three times daily until recovery for a
maximum of 6 days (Hamza et al., 1999). The primary outcome
parameter was mean stool weight, which was signiﬁcantly smaller
in the racecadotril as compared to the placebo group (355± 35
vs. 499± 46 g, respectively). Secondary outcome parameters for
which racecadotril was signiﬁcantly superior to placebo included
number of diarrhoic stools after 1 day of treatment 4.3 ± 0.4 vs.
5.4± 0.4, respectively) and percentage of patients passing at least
one formed stool on the second day of treatment (15.6 vs. 5.3%,
respectively). The incidence of reported adverse events was 3.1%
with racecadotril vs. 5.3% with placebo; abdominal distension,
not classiﬁed as an adverse event in this study, was 5.6% with
racecadotril vs. 18.2% with placebo.
Following registration in 1992, one additional double-blind,
randomized, placebo-controlled trial was performed in 110 men
with cholera, in which 100mg racecadotril was administered every
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Table 1 | Efficacy of racecadotril in the treatment of acute diarrhea in adults.
Outcome parameter Number of patients Racecadotril Comparator Reference
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES INADULTSWITHACUTE DIARRHEA
Time to recovery, h 54–55 per group vs. 49§ 65.0–69.9 72.0 data on ﬁle
% Probability for recovery on day 4 95 vs. 98 75* 37 Baumer et al. (1992)
Stool weight, g 32 vs. 38 355±35* 499±46 Hamza et al. (1999)
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES INADULTSWITH CHOLERA
Total stool output, g 54 vs. 56 315±31 280±21 Alam et al. (2003)
STUDIES INADULTSWITHACUTE DIARRHEAASSOCIATEDWITH CANCER CHEMOTHERAPY (5-FLUORO-URACIL)
Number of stools per day 15 (sequential racecadotril vs. no treatment) 4.9* 6.3 Dorval et al. (1995)
STUDIES INADULTSWITH DELAYED DIARRHEA DUE CANCER CHEMOTHERAPY (IRINOTECAN)
Treatment responder 11 36% – Saliba et al. (1998)
Prophylaxis of diarrhea 68 vs. 68 no treatment 55% 59% Ychou et al. (2000)
OCTREOTIDE-CONTROLLED STUDIES INADULTSWITHTREATMENT-RESISTANT DIARRHEA INAIDS PATIENTS
Stools/day 13 (cross-over) −2.4* −1.4 Beaugerie et al. (1996)
DOUBLE-BLIND, LOPERAMIDE-CONTROLLED STUDIES INADULTSWITHACUTE DIARRHEA
Time to diarrhea resolution, days 37 vs. 32 2.2±0.2 2.3±0.2 Roge et al. (1993)
Number of stools 82 vs. 75 3.5±0.5 2.9±0.4 Vetel et al. (1999)
Duration of diarrhea, h 473 vs. 472 55.0 55.0 Prado (2002)
Duration of diarrhea, h 31 vs. 31 19.5 13.0 Wang et al. (2005)
Time recovery, h 30 vs. 31 36±4* 63±6 Gallelli et al. (2010)
*p<0.05 vs. comparator; §dose-ranging study using 30, 100, and 300mg racecadotril thrice daily. For details on individual studies see main text Section “Studies in
the Gastro-Intestinal Tract.”
4 h until recovery for a maximum of 72 h as an adjunct to stan-
dard treatment (Alam et al., 2003). Both treatments did not differ
signiﬁcantly with regard to total stool output, duration of diar-
rhea or patients with resolution of diarrhea within 72 h. Adverse
events noted as per-protocol such as vomiting, reappearance of
dehydration, abdominal pain, headache, or anorexia were not dif-
ferent between the treatment groups. Taken together these studies
consistently demonstrate efﬁcacy of racecadotril as compared to
placebo with similar adverse event incidences with both treat-
ments. However, it should be noted that treatment regimens and
outcome parameter varied considerably between studies.
STUDIES IN OTHER FORMS OF ADULT DIARRHEA
Some studies have been performed with racecadotril in the con-
text of diarrhea associated with cancer chemotherapy. In a pilot
study in 15 cancer patients treated with 5-ﬂuoro-uracil were given
a daily dose of 300mg/d racecadotril for 7 days for the treatment
of acute diarrhea (Dorval et al., 1995). As compared to the control
period, i.e., earlier cycle of chemotherapy, the number of stools
per day was reduced in each patient with a statistically signiﬁcant
reduction of mean number from 6.3 to 4.9 and the number of days
with liquid stools signiﬁcantly dropped from 4.7 to 2.4.
Delayed onset diarrhea is a dose-limiting side-effect of the
second-line anti-cancer drug irinotecan, which is often used in
the treatment of colon cancer. Among patients exhibiting delayed
diarrheaupon irinotecan treatment,4 out of 11patients responded
to 100mg racecadotril thrice daily in one cohort, whereas 9 of
10 patients responded to a combination of racecadotril and lop-
eramide (p< 0.02 vs. racecadotril alone) (Saliba et al., 1998). In a
randomized open-label study 136 patients receiving a total of 714
irinotecan chemotherapy cycles received 300mg/d racecadotril for
15 days as a prophylactic treatment or no prophylactic treatment
but the two groups did not differ signiﬁcantly in the incidence or
severity of delayed diarrhea (Ychou et al., 2000).
In an open, randomized cross-over study the efﬁcacy of
100–300mg racecadotril thrice daily and 50–150μg octreotide
thrice daily was compared in 13 treatment-resistant diarrhea
in AIDS patients (Beaugerie et al., 1996). From a baseline of
7.0± 1.2 stools/day racecadotril caused a signiﬁcant reduction to
4.6± 1.1 stools/day, whereas octreotide caused a non-signiﬁcant
reduction to only 5.6± 1.2 stools/day. Daily lipid output was
increasednon-signiﬁcantly by racecadotril,butwasnearly doubled
with octreotide.
RACECADOTRIL CLINICAL STUDIES VS. PLACEBO AND OPEN STUDIES
IN CHILDREN
Based upon the results of racecadotril in the treatment of acute
diarrhea in adults, several studies have explored its use in the
treatment of acute diarrhea in children. The data of all controlled
studies with racecadotril in the treatment of acute diarrhea in chil-
dren are summarized for efﬁcacy in Table 2 and for adverse events
in Figure 3. In the ﬁrst of such studies 135 boys aged 3–35months
including 73 with a veriﬁed rotavirus infection with 1.5mg/kg
racecadotril every 8 h or placebo in a randomized, double-blind
study with both treatments being administered on top of oral
rehydration solution (Salazar-Lindo et al., 2000). Total stool out-
put in the ﬁrst 48 h of treatment, the primary study endpoint, was
157± 27 g/kg with racecadotril as compared to 331± 39 g/kg with
placebo (p< 0.001). The duration of diarrhea was signiﬁcantly
shorter with racecadotril (28 h regardless of rotavirus status) than
with placebo treatment (72 and 52 h in rotavirus-positive and –
negative boys, respectively).Moreover, the amount of required oral
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FIGURE 2 | Incidence of adverse events (upper panel) and rebound
constipation (lower panel) in controlled studies with racecadotril in
the treatment of acute diarrhea in adults. *p<0.05 vs. comparator; n.s.,
not signiﬁcant; n.r., not reported. For study details see main text, for
corresponding efﬁcacy results seeTable 1.
rehydration solution was also signiﬁcantly less with racecadotril
treatment. Adverse events were reported in 7 of 68 and 5 of 67
children receiving racecadotril and placebo, respectively; 51 and
52% reported vomiting at at least some point during treatment,
and study withdrawal occurred in 9 and 14 patients, respectively.
A second double-blind, placebo-controlled randomized study
of very similar design with racecadotril on top of oral rehydra-
tion solution was performed in 173 infants aged 3 months to
4 years, except that this study included children of both genders
(Cezard et al., 2001). Total stool output was signiﬁcantly lower
FIGURE 3 | Incidence of adverse events in controlled studies with
racecadotril in the treatment of acute diarrhea in children. n.r., not
reported; ORS, oral rehydration solution. Note that group differences did
not reach statistical signiﬁcance with the given number of patients. For
study details see main text, for corresponding efﬁcacy results seeTable 2.
by 60% (95% conﬁdence interval 43–88%) with racecadotril as
compared to placebo, and this was again independent of rotavirus
status. Stool output in the ﬁrst 24 h of treatment, a secondary
endpoint, was also signiﬁcantly less with racecadotril. The time
to recovery was also signiﬁcantly shorter with racecadotril in a
Kaplan–Meier analysis. Moreover, the need for oral rehydration
solution on the second day of treatment was also signiﬁcantly
lower with racecadotril treatment. Adverse events were reported
by nine patients of each group, but abdominal distension was not
noted in either treatment group.
In a third study the effect of racecadotril given as adjunct
to oral rehydration solution was compared to rehydration alone
in 166 children aged 3–34months in a randomized open-label
study (Cojocaru et al., 2002). The primary endpoint was the
number of medical exams within a week after start of treatment
which was signiﬁcantly lower with racecadotril than without (14
vs. 27). Secondary endpoints the number of stools within the
ﬁrst 48 h (6.8± 3.8 vs. 9.5± 4.5) and the duration of diarrhea
(97.2± 35.6 vs. 137.7± 42.4 h) were also signiﬁcantly less in the
racecadotril group.
In an open-label parallel group study 189 children aged
3–36months were treated with oral rehydration solution or
racecadotril (10 or 30mg thrice daily for children with 9–13 or
>13 kg body weight, respectively) on top of such solution until
two normal stools were observed or no bowel movement occurred
within 12 h for up to 7 days (Santos et al., 2009). The primary
endpoint, number of bowel movements in the ﬁrst 48 h after ini-
tiation of treatment, did not differ signiﬁcantly between the two
treatments (4.1± 2.7 vs. 3.8± 2.4 for control and racecadotril,
respectively), and the duration of gastroenteritis, a secondary
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Table 2 | Efficacy of racecadotril in the treatment of acute diarrhea in children.
Outcome parameter Number of patients Racecadotril Comparator Reference
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES IN CHILDRENWITHACUTE DIARRHEA
Stool output, g/kg 68 vs. 65 157±27* 331±39 Salazar-Lindo et al. (2000)
Stool output, g/h 84 vs. 82 9* 15 Cezard et al. (2001)
OPEN-LABEL CONTROLLED STUDIES (VS. REHYDRATIONALONE) IN CHILDRENWITHACUTE DIARRHEA
Medical exams within 1week of treatment 81 vs. 83 14* 27 Cojocaru et al. (2002)
Number of stools in ﬁrst 48 h 88 vs. 91 3.8±2.4 4.1±2.7 Santos et al. (2009)
OPEN-LABEL OBERVATIONAL STUDIES IN CHILDRENWITHACUTE DIARRHEA
Time to relief, h 3873 18.5±12.5 n.a. Chacon (2010)
DOUBLE-BLIND, LOPERAMIDE-CONTROLLED STUDIES IN CHILDRENWITHACUTE DIARRHEA
Number of diarrhoic stools until recovery 52 vs. 50 2.7±0.4 2.1±0.4 Turck et al. (1999)
n.a., Not applicable; *p<0.05 vs. comparator.
endpoint, also differed numerically but not signiﬁcantly (4.7 ± 2.2
vs. 4.0± 2.1 days, respectively). The incidence of adverse events
was similar in both treatment groups (20.2 vs. 19.1%,respectively).
In an open-label study 3873 children aged 3months to 12 years
were treated with 1.5mg/kg thrice daily (Chacon, 2010). The pri-
mary endpoint of that study was time to relief, time from start
of treatment to last watery bowel movement, which was reached
after 18.5± 12.5 h (95% conﬁdence interval 17.9–19.0 h). Using
the very large number of children in this study, the authors have
performed a multiple regression analysis to explore factors affect-
ing drug performance. Among a range of potential explanatory
variables diarrhea severity was the only with a signiﬁcant and
independent weight on racecadotril effectiveness, explaining 23%
of time to relief variance, but even in severe cases mean time to
relief was less than 24 h. Speciﬁc adverse event incidence was not
reported, but overall tolerability was rated as excellent or good in
95.9% of cases.
While some of the above mentioned randomized pediatric
studies have been systematically reviewed in the past (Szajew-
ska et al., 2007; Tormo et al., 2008), those analyses covered only
part of the existing trial databases. More importantly, an indi-
vidual patient meta-analysis of nine pediatric studies with raw
data available for analysis from 1384 children has been reported
more recently which also included some studies that had not
been reported before as full papers (Lehert et al., 2011). The pro-
portion of children with recovery was higher with racecadotril
treatment with a hazard ratio of 2.04 (95% conﬁdence inter-
val 1.85–2.32). For in-patient studies, the ratio of mean stool
output racecadotril/placebo was 0.59 (0.51–0.74, p< 0.001), for
out-patient studies, the ratio of the mean number of diarrhoic
stools racecadotril/placebo was 0.63 (0.51–0.74, p< 0.001).
Accordingly, a survey of treatment patterns among all ofﬁce-
based pediatricians in France found racecadotril to be prescribed
by 62% of pediatricians as compared to only 28% prescribing
loperamide (Uhlen et al., 2004). In line with the above stud-
ies, as an addition to oral rehydration treatment, racecadotril
is being recommended for the treatment of acute diarrhea in
children by recent guidelines, e.g., from the World Gastroenterol-
ogy Organisation (World Gastroenterology Association, 2008),
the European Society of Pediatric Gastroenterology, Hepatology
and Nutrition/European Society for Pediatric Infectious Diseases
(Guarino et al., 2008), a guideline panel from Spain and Latin
America (Gutierrez Castrelion et al., 2010), and the German
Society for Pediatric Gastroenterology and Nutrition (Koletzko
and Lentze, 2008). Similarly, a very recent international panel of
experts from France, Ireland, Italy, Malaysia, Peru, Spain, USA,
and Vietnam emphasized that oral rehydration solution is the
basis of the treatment of acute diarrhea in children; the use of
loperamide was discouraged, whereas racecadotril was recognized
as an option for additional active treatment on top of rehydration
solution (Guarino et al., 2012).
RACECADOTRIL CLINICAL STUDIES VS. LOPERAMIDE (ADULTS AND
CHILDREN)
As loperamide has been the primary medical treatment of acute
diarrhea for a long time, particularly in adults, six studies have
reported direct comparisons of the efﬁcacy and tolerability of
racecadotril and loperamide including one study in children.
Roge et al. (1993) reported a double-blind controlled study in
which 100mg racecadotril was compared to 1.33mg loperamide
(two doses at start of treatment, followed by one dose every 8 h)
in 37 vs. 32 patients, respectively. The study did not report a pri-
mary endpoint but rather several outcome parameters in parallel
including physician evaluation of efﬁcacy, time to diarrhea reso-
lution, abdominal pain for more than 1 day, abdominal distension
for more than 1 day, duration of abdominal distension and sec-
ondary constipation. Racecadotril was numerically superior to
loperamide for all of these endpoints, and the difference reached
statistical signiﬁcance for the latter three. The authors did not
speciﬁcally report incidence of adverse events but secondary con-
stipation can be considered as such and was found signiﬁcantly
less frequent in racecadotril as compared to loperamide-treated
patients (8.1 vs. 31.3%).
A second randomized,double-blind,double-placebo-controlled
study compared the efﬁcacy and safety of 100mg racecadotril
thrice daily with that of 2mg loperamide after each diarrhoic stool
in 82 and 75 patients, respectively, administered until recovery for
a maximum of 7 days (Vetel et al., 1999). Both groups passed a
similar number of stools (3.5 ± 0.5 vs. 2.9± 0.4) and had a similar
duration of diarrhea (14.9 ± 2.0 vs. 13.7± 2.2 h). Adverse events
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were reported in 7.4% of racecadotril and 12% of loperamide
patients, and rebound constipation was experienced by 9.8% of
racecadotril vs. 18.7% of loperamide patients.
The third and largest direct head-to-head study compared 473
patients receiving 100mg racecadotril thrice daily with 472 patient
receiving 2mg loperamide thrice daily in a single-blind design
(Prado, 2002). The primary efﬁcacy criterion was duration of
diarrhea, deﬁned as time between start of treatment and appear-
ance of ﬁrst formed stool; this was 55.0 h in both groups (95%
conﬁdence interval 50.0–65.0 and 48.0–66.0 h in the racecadotril
and loperamide group, respectively). The median duration of
abdominal pain was similar in both groups, but difference in
pain intensity between start and end of study was signiﬁcantly
in favor of racecadotril; moreover, a signiﬁcantly greater per-
centage of patients reported residual pain at study end with
loperamide as compared to racecadotril treatment (7 vs. 3%).
Rebound constipation (objectively deﬁned as 36 h without passing
stool) was signiﬁcantly more frequent with loperamide than with
racecadotril treatment (25 vs. 16%). The incidence of reported
adverse events was also signiﬁcantly greater with loperamide than
with racecadotril (23.9 vs. 14.2%).
A fourth randomized study compared 31 patients receiving
100mg racecadotril thrice daily to 31 patients receiving 2mg
loperamide twice daily in a single-blind manner (Wang et al.,
2005). The primary endpoint was duration of diarrhea, which
did not differ signiﬁcantly between treatments (median 19.5 vs.
13.0 h for racecadotril and loperamide, respectively). Duration of
abdominal pain, abdominal distension, anal burning, and nau-
sea also did not differ signiﬁcantly between treatments. Adverse
events were reported in 25.0% of racecadotril and 22.0% of lop-
eramide patients.Among these rebound constipationwas reported
in four andnine racecadotril and loperamide patients, respectively,
whereas itching was found in two racecadotril but no loperamide
patients.
A ﬁfth double-blind, randomized study compared 100mg
racecadotril thrice daily to loperamide (4mg starting dose, fol-
lowed by 2mg after each unformed stool for a maximum of
8mg/d) in 30 and 31 patients, respectively, being administered
until recovery which was deﬁned by two consecutive normal
stools or no stools in a 12-h period (Gallelli et al., 2010). In
contrast to the other studies, this one recruited only elderly nurs-
ing home residents with acute diarrhea (mean age 82 years). The
primary endpoint was time to recovery which was met signiﬁ-
cantly earlier with racecadotril than with loperamide treatment
(36± 4 vs. 63± 6 h). Secondary endpoints included duration of
abdominal pain, number of diarrhea episodes, and total stool
output in the intention-to-treat and in the per-protocol popu-
lations; racecadotril was numerically superior to loperamide all
of these, and this reached statistical signiﬁcance in several cases.
In 50% of patients loperamide was ineffective within 4 days;
these were switched to racecadotril resulting in rapid normal-
ization of all symptoms. Adverse events were reported in 12%
of racecadotril and 60% of loperamide patients; the latter per-
centage is much higher than in other loperamide studies, prob-
ably due to the elderly population being studied. Speciﬁcally,
nausea and rebound constipation were noted more frequently
with loperamide than with racecadotril, whereas abdominal pain,
headache, and anorexia were seen similarly with both treatments.
Based on genotyping for cytochrome P450 3A4 and 2C8 it was
excluded that the group differences were not attributable to the
presence of ultra-rapid or poor metabolizers. In a pharmacoeco-
nomic analysis the average cost in the loperamide group was twice
as high as in the racecadotril group (C 91.99 vs. C 44.85).
A sixth randomized study directly comparing racecadotril and
loperamide in the treatment of acute diarrhea was performed in
a pediatric population with a mean age of 4.7 years (range 2–
10 years) in a double-blind, double-placebo design (Turck et al.,
1999). Fifty-two children received 1.5mg/kg racecadotril thrice
daily and 50 received 0.03mg/kg loperamide thrice daily. The pri-
mary endpoint was number of passed stools until recovery which
did not differ signiﬁcantly between the two groups (2.7 ± 0.4
with racecadotril and 2.1± 0.4 with loperamide). The mean dura-
tion of diarrhea also did not differ signiﬁcantly between groups
(10.7± 1.7 h with racecadotril and 8.8± 2.3 h with loperamide).
Adverse events were noted in 11.5% of racecadotril and 22% of
loperamide patients. Therewere only statistically signiﬁcant differ-
ences between the two treatments: rebound constipation (36.5%
of racecadotril and 58% of loperamide patients) and need for
concomitant medication (anti-emetics 5 vs. 8, analgesics 0 vs. 3
patients, oral rehydration 0 vs. 2, and laxatives 0 vs. 1 patient on
racecadotril and loperamide, respectively.
Taken together these six studies demonstrate that the efﬁcacy
of racecadotril and loperamide in the treatment of acute diarrhea
did not differ signiﬁcantly for some endpoints in some studies,
but that racecadotril was signiﬁcantly more effective for at least
some endpoints in some studies. The incidence of adverse events
also was similar in some studies but signiﬁcantly less frequent
with racecadotril in some other studies. A much lower frequency
of rebound constipation was seen with racecadotril in almost all
studies. Thus, in comparison to loperamide racecadotril appeared
to be superior in efﬁcacy and tolerability when all studies are taken
into consideration.
While the mechanisms underlying differential effects of
racecadotril and loperamide in acute diarrhea have not been fully
established, two candidates have emerged: Firstly, loperamide pref-
erentially acts on μ-opioid receptors (Dehaven-Hudkins et al.,
1999), whereas endogenous enkephalines active both μ- and δ-
receptors (Huighebaert et al., 2003). Secondly,NEP inhibition will
not only increase exposure to endogenous enkephalines but also
to endogenous neuropeptide Y and, possibly, peptide YY, both of
which have strong anti-secretory effects in the gut (Playford and
Cox, 1996).
SAFETY AND TOLERABILITY
As summarized in Figure 2 for adult and Figure 3 for pedi-
atric patients with acute diarrhea, the incidence of adverse events
reported during treatmentwith racecadotril was consistently simi-
lar to that with placebo and similar to or signiﬁcantly less frequent
than that with loperamide. Of note secondary constipation was
consistently less frequent with racecadotril than with loperamide;
for details see speciﬁc study descriptions in section 6. Therefore,
the following will summarize published ﬁndings on non-clinical
toxicity studies and will highlight clinical ﬁndings with potential
relevance for safety and tolerability.
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With regard to general toxicity, no relevant ﬁndings were
reported for single doses up to 2000mg/kg and for chronic
doses up to 100mg/kg in dogs (Maertins et al., 2000). In
mice no overt toxicity was observed upon i.p. treatment with
50mg/kg racecadotril for 10 days (Lecomte et al., 1986). In a
study with newborn gnotobiotic piglets an oral dose of 130mg/kg
racecadotril produced no signs of neurotoxicity and no deaths,
whereas an equivalent high dose of 5mg/kg loperamide resulted
in death in three out of four piglets (Duval-Ilfah et al., 1999).
In monkeys 12months of treatment with up to 100 times
the therapeutic human dose did not produce any toxic effects
(Lecomte, 2000). Single doses of up to 2000mg have been
administered in healthy volunteers without ill effects (Lecomte,
2000).
Several studies have speciﬁcally explored potential adverse
events related to airway function, breathing and allergy. As sub-
stance P also is a NEP substrate, the effect of racecadotril on
responses to exogenous substance P has been explored. In guinea
pigs racecadotril enhanced pulmonary substance P response (Löt-
vall et al., 1990). In humans 200mg racecadotril enhanced the
ﬂare response to substance P in asthmatic subjects (Nichol et al.,
1992), and a dose of 300mg racecadotril enhanced the substance
P-induced decrease in nasal conductance in healthy subjects and
those with allergic rhinitis (Lurie et al., 1994). There is one case
report of a 3-year-old boy weighing 20 kg and reporting general-
ized edema with itching and aphonia after 2 days of treatment with
30mg racecadotril; upon additional testing this was classiﬁed as a
non-allergic hypersensitivity response (Nucera et al., 2006). While
respiratory depression is a typical effects of direct opioid receptor
agonists with penetration to the central nervous system such as
morphine, no respiratory depression was noted with acute i.v. or
i.p. racecadotril doses of up to 100mg/kg in mice (Lecomte et al.,
1986).
Finally, there were a few isolated ﬁndings from animal studies.
In rats racecadotril and thiorphan were reported to enhance the
duration but not the frequency of uterine contractions in peri-
parturient animals (Adjroud, 1995). Also in rats the angiotensin
converting enzyme inhibitor captopril produced plasma extrava-
sation; while racecadotril alone did not mimick this, it enhanced
the captopril response (Sulpizio et al., 2004). However, both
of these studies are difﬁcult to place into context as no corre-
sponding adverse events have been reported in patients. Thus,
the overall non-clinical and clinical studies demonstrate that
racecadotril is a safe drugwith an overall tolerability proﬁle similar
to placebo.
CONCLUSION
Racecadotril is a low potency inhibitor of NEP, but upon oral
administration it is rapidly and effectively metabolized to the
potentNEP inhibitor thiorphan,with the latter not exhibiting pen-
etration into the central nervous system.NEP inhibition affects the
abundance of several endogenous peptides with enkephalins and
ANP apparently being most important. Elevated exposure to ANP
appears to underly most cardiovascular effects of racecadotril;
while these tend to be beneﬁcial they appear quantitatively insuf-
ﬁcient to warrant therapeutic use in comparison to other avail-
able drug classes. Elevation of enkephalin exposure appears to
underly most central nervous effects, most notably analgesia, but
the pain relieving effects are inconsistent across animal models.
Increased exposure to peripheral endogenous enkephalins appears
to underly the gastro-intestinal racecadotril effects. Most promi-
nent among them is an antisecretory effect in the gut which, in
contrast to directμ-opioid receptor agonists, occurs in the absence
of effects on gastro-intestinal transit time. The clinical correlate
of these ﬁndings is therapeutic efﬁcacy against acute diarrhea
in adults and children with a tolerability proﬁle similar to that
of placebo. In multiple direct comparative studies in different
patients populations (children, adults, elderly), countries (West-
ern Europea, Latin Amercia, Asia), and settings (out-patients, in-
patients, nursing home residents) racecadotril was at least as effec-
tive as loperamide, and in several of those studies exhibited signiﬁ-
cantly better tolerability than loperamide. Most notably, rebound
constipation was consistently less frequent with racecadotril than
with loperamide; while this is primarily a tolerability beneﬁt, it
may also be relevant with regard to the efﬁcacy of clearance of
infectious organisms as demonstrated in one study. Of note, study
designs andparticularly treatment endpoints differed considerably
between studies. This can be seen as a weakness because it makes
inter-study comparisons more difﬁcult; however, it can also be
seen as a beneﬁt because consistent therapeutic effects across so
manydifferent settingswitness rather robust efﬁcacy and tolerabil-
ity. While additional studies appear warranted several guidelines,
speciﬁcally in pediatric indications, now recommend including
racecadotril in the management of acute diarrhea. Whether other
forms of diarrhea, e.g., in the context of cancer chemotherapy, also
beneﬁt from racecadotril treatment is not fully clear.
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